解码药物耐受性:了解Rv0274基因在异化物耐受性中的作用
Min Li1, Yun Wang1, Xiaohong Xiang2
1Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Frontiers in microbiology
|December 15, 2025
概括
Rv0274基因,也称为MSMEG_0608,对菌根菌中异化物耐受性至关重要. 它的缺失会损害耐药性,突出其在结核病治疗策略中的作用.
科学领域:
- 微生物学 微生物学
- 分子生物学分子生物学
- 药物耐药性机制 药物耐药性机制
背景情况:
- 异化 (INH) 是结核病 (TB) 的一线药物.
- 在Mycobacterium结核病中INH耐受性的机制尚未完全理解.
- Rv0274基因是INH耐受性的潜在贡献者.
研究的目的:
- 调查Rv0274/MSMEG_0608在异化物耐受性中的作用.
- 阐明涉及Rv0274/MSMEG_0608的监管网络及其对INH耐药性的影响.
- 使用Mycobacterium smegmatis作为研究INH耐受性的模型生物.
主要方法:
- 在Mycobacterium smegmatis.中产生MSMEG_0608淘汰菌株.
- 药物敏感性测试和生长曲线分析.
- 转录基因分析,RT-qPCR,基因补充和基因淘汰实验.
主要成果:
- 删除MSMEG_0608显著降低了异化物耐受性.
- Rv0274/MSMEG_0608 积极调节异化物耐受性.
- Rv0274/MSMEG_0608影响与Rv0273c/MSMEG_0606和inHA相关的基因的表达.
结论:
- 通过负调节与Rv0273c (MSMEG_0606) 相关的基因,Rv0274 (MSMEG_0608) 在异化物耐受性中发挥着关键作用.
- 这一规定影响了INH表达,这是INH易感性的关键决定因素.
- 这项研究提供了对真菌细菌INH耐受性的机制性见解,为进一步研究铺平了道路.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Transduction
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome are...